183 related articles for article (PubMed ID: 31926117)
1. Anti-tumour immune response in GL261 glioblastoma generated by Temozolomide Immune-Enhancing Metronomic Schedule monitored with MRSI-based nosological images.
Wu S; Calero-Pérez P; Villamañan L; Arias-Ramos N; Pumarola M; Ortega-Martorell S; Julià-Sapé M; Arús C; Candiota AP
NMR Biomed; 2020 Apr; 33(4):e4229. PubMed ID: 31926117
[TBL] [Abstract][Full Text] [Related]
2. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
[TBL] [Abstract][Full Text] [Related]
3. Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches.
Wu S; Calero-Pérez P; Arús C; Candiota AP
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233585
[TBL] [Abstract][Full Text] [Related]
4. Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma.
Delgado-Goñi T; Julià-Sapé M; Candiota AP; Pumarola M; Arús C
NMR Biomed; 2014 Nov; 27(11):1333-45. PubMed ID: 25208348
[TBL] [Abstract][Full Text] [Related]
5. Immune System-Related Changes in Preclinical GL261 Glioblastoma under TMZ Treatment: Explaining MRSI-Based Nosological Imaging Findings with RT-PCR Analyses.
Calero-Pérez P; Wu S; Arús C; Candiota AP
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071393
[TBL] [Abstract][Full Text] [Related]
6. MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis.
Delgado-Goñi T; Ortega-Martorell S; Ciezka M; Olier I; Candiota AP; Julià-Sapé M; Fernández F; Pumarola M; Lisboa PJ; Arús C
NMR Biomed; 2016 Jun; 29(6):732-43. PubMed ID: 27061401
[TBL] [Abstract][Full Text] [Related]
7. Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice.
Zhao K; Calero-Pérez P; Bopp MHA; Möschl V; Pagenstecher A; Mulero-Acevedo M; Vázquez M; Barcia C; Arús C; Nimsky C; Rusch T; Bartsch JW; Candiota AP
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139457
[TBL] [Abstract][Full Text] [Related]
8. Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia.
Dang W; Xiao J; Ma Q; Miao J; Cao M; Chen L; Shi Y; Yao X; Yu S; Liu X; Cui Y; Zhang X; Bian X
Brain Tumor Pathol; 2021 Jul; 38(3):189-200. PubMed ID: 34231121
[TBL] [Abstract][Full Text] [Related]
9. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
[TBL] [Abstract][Full Text] [Related]
10. Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization.
Li Z; Fu WJ; Chen XQ; Wang S; Deng RS; Tang XP; Yang KD; Niu Q; Zhou H; Li QR; Lin Y; Liang M; Li SS; Ping YF; Liu XD; Bian XW; Yao XH
J Exp Clin Cancer Res; 2022 Feb; 41(1):74. PubMed ID: 35193644
[TBL] [Abstract][Full Text] [Related]
11. Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells.
Villamañan L; Martínez-Escardó L; Arús C; Yuste VJ; Candiota AP
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33810611
[TBL] [Abstract][Full Text] [Related]
12. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
13. Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction.
Núñez LM; Romero E; Julià-Sapé M; Ledesma-Carbayo MJ; Santos A; Arús C; Candiota AP; Vellido A
Sci Rep; 2020 Nov; 10(1):19699. PubMed ID: 33184423
[TBL] [Abstract][Full Text] [Related]
14. The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment.
Patties I; Kallendrusch S; Böhme L; Kendzia E; Oppermann H; Gaunitz F; Kortmann RD; Glasow A
J Exp Clin Cancer Res; 2019 Oct; 38(1):420. PubMed ID: 31639020
[TBL] [Abstract][Full Text] [Related]
15. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model.
Banissi C; Ghiringhelli F; Chen L; Carpentier AF
Cancer Immunol Immunother; 2009 Oct; 58(10):1627-34. PubMed ID: 19221744
[TBL] [Abstract][Full Text] [Related]
16. Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
Sun C; Yu Y; Wang L; Wu B; Xia L; Feng F; Ling Z; Wang S
J Exp Clin Cancer Res; 2016 Feb; 35():32. PubMed ID: 26872471
[TBL] [Abstract][Full Text] [Related]
17. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
Wu J; Waxman DJ
Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of temozolomide for recurrent glioblastoma multiforme.
Chen C; Xu T; Lu Y; Chen J; Wu S
Eur J Neurol; 2013 Feb; 20(2):223-30. PubMed ID: 22680781
[TBL] [Abstract][Full Text] [Related]
19. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Karachi A; Yang C; Dastmalchi F; Sayour EJ; Huang J; Azari H; Long Y; Flores C; Mitchell DA; Rahman M
Neuro Oncol; 2019 Jun; 21(6):730-741. PubMed ID: 30668768
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]